Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy

被引：29

作者：

Clezardin, P. ^{[1
]}

Massaia, M. ^{[2
,3
,4
]}

机构：

[1] Univ Lyon 1, INSERM, U664, Res Unit,Fac Med Laennec, F-69372 Lyon 08, France

[2] Osped San Giovanni Battista Torino, Ctr Ric Med Sperimentale CeRMS, Lab Ematol Oncol, I-10126 Turin, Italy

[3] Osped San Giovanni Battista Torino, Div Univ Ematol, I-10126 Turin, Italy

[4] Univ Turin, I-10126 Turin, Italy

来源：

CURRENT PHARMACEUTICAL DESIGN | 2010年 / 16卷 / 27期

关键词：

Bisphosphonate; zoledronate; IPP; gamma delta T cell; immunotherapy; cancer; DELTA-T-CELLS; ZOLEDRONIC ACID; TUMOR-CELLS; IN-VITRO; MEVALONATE METABOLITES; ANTITUMOR-ACTIVITY; EX-VIVO; ACTIVATION; PYROPHOSPHATE; PAMIDRONATE;

D O I：

10.2174/138161210793563545

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that N-BPs have anticancer activity. Some of the activities associated with N-BPs are observed in human gamma delta T cells that straddle the interface of innate and adaptive immunity and have potent anti-tumour activity. This review examines the molecular and cellular mechanisms through which N-BPs stimulate the expansion and cytotoxic activity of human gamma delta T cells. In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy.

引用

页码：3007 / 3014

页数：8

共 64 条

[1] Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma [J].

Abe, Yu ;

Muto, Masato ;

Nieda, Mie ;

Nakagawa, Yasunori ;

Nicol, Andrew ;

Kaneko, Touru ;

Goto, Shigenori ;

Yokokawa, Kiyoshi ;

Suzuki, Kenshi .

EXPERIMENTAL HEMATOLOGY, 2009, 37 (08) :956-968

[2] Isopentenyl pyrophosphate-activated CD516+ γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma [J].

Alexander, Alan A. Z. ;

Maniar, Amudhan ;

Cummings, Jean-Saville ;

Hebbeler, Andrew M. ;

Schulze, Dan H. ;

Gastman, Brian R. ;

Pauza, C. David ;

Strome, Scott E. ;

Chapoval, Andrei I. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4232-4240

[3] FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways [J].

Angelini, DF ;

Borsellino, G ;

Poupot, M ;

Diamantini, A ;

Poupot, R ;

Bernardi, G ;

Poccia, F ;

Fournié, JJ ;

Battistini, L .

BLOOD, 2004, 104 (06) :1801-1807

[4] Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma [J].

Aviles, Agustin ;

Nambo, Maria J. ;

Neri, Natividad ;

Castaneda, Claudia ;

Cleto, Sergio ;

Huerta-Guzman, Judith .

MEDICAL ONCOLOGY, 2007, 24 (02) :227-230

[5] Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].

Bennouna, Jaafar ;

Bompas, Emmanuelle ;

Neidhardt, Eve Marie ;

Rolland, Frederic ;

Philip, Irene ;

Galea, Celine ;

Salot, Samuel ;

Saiagh, Soraya ;

Audrain, Marie ;

Rimbert, Marie ;

Micheaux, Sylvie Lafaye-de ;

Tiollier, Jerome ;

Negrier, Sylvie .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609

[6] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, M ;

Blacklock, H ;

Bell, R ;

Simeone, JF ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602

[7]

Boudou-Rouquette P, 2009, ANN ONCOL, V20, P1747, DOI [10.1093/annonc/mdp378, 10.1093/annonc/mdp385]

[8] Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma [J].

Buckle, C. H. ;

Neville-Webbe, H. L. ;

Croucher, P. I. ;

Lawson, M. A. .

CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (11) :1272-1283

[9] In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].

Burjanadze, Maka ;

Condomines, Maud ;

Reme, Thierry ;

Quittet, Philippe ;

Latry, Pascal ;

Lugagne, Cecile ;

Romagne, Francois ;

Morel, Yanis ;

Rossi, Jean Francois ;

Klein, Bernard ;

Lu, Zhao Yang .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :206-216

[10]

Caccamo N, 2008, EXPERT OPIN BIOL TH, V8, P875, DOI [10.1517/14712598.8.7.875, 10.1517/14712598.8.7.875 ]

← 1 2 3 4 5 6 7 →